Our latest articles
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.
AACR 2023 – Moderna's immunotherapeutic splash
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
Daiichi torches Esperion’s Nexletol milestone promises
Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Amylyx aces launch as tofersen’s big date approaches
Breakeven beckons for Amylyx.
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.